Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Biogen Announces Second Positive Phase 2 Litifilimab Trial
Biogen announced positive results from the Phase 2 AMETHYST study for litifilimab in cutaneous lupus erythematosus (CLE), demonstrating a significant reduction in skin disease activity. This marks the second positive Phase 2 trial for litifilimab, which is being investigated as a potential first targeted therapy for CLE, a condition currently lacking approved targeted treatments. The drug also received FDA Breakthrough Therapy Designation, indicating its potential to address a significant unmet medical need for patients.